FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Noven Pharmaceuticals Daytrana Recall

Daytrana (methylphenidate) transdermal system patch, Delivers 15 mg over 9 hours (1

Noven Pharmaceuticals, Inc. · Miami, FL

Risk level
Class II
Reported by FDA
Jun 20, 2012
Recall ID
D-1374-2012
Check your lot numberHow we source this data

Summary

Noven Pharmaceuticals recalled Daytrana starting Jul 5, 2011. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1374-2012 on Jun 20, 2012. Reason: Miscalibrated and/or Defective Delivery System: Out of Specification results for mechanical peel force and/or the z-statistic value which relates to the patient's ability to remove the release liner from the patch adhesive prior to administration. Status: Terminated.

Why it was recalled

Miscalibrated and/or Defective Delivery System: Out of Specification results for mechanical peel force and/or the z-statistic value which relates to the patient's ability to remove the release liner from the patch adhesive prior to administration.

Product description

Daytrana (methylphenidate) transdermal system patch, Delivers 15 mg over 9 hours (1.6 mg/hr), 1 patch per pouch (NDC 54092-553-01), packaged in 30-count patches per box (NDC 54092-553-30), Rx only, Manufactured for Shire US Inc., Wayne, PA 19087; by Noven Pharmaceuticals, Inc., Miami, FL 33186.

Lot numbers, UPCs & expiration codes

Lot #: 43783, Exp 01/12

Where it was sold

Nationwide and Puerto Rico.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1374-2012
Classification
Class II
Status
Terminated
Recall initiated
Jul 5, 2011
FDA report date
Jun 20, 2012
Quantity
244,320 patches
Recall type
Voluntary: Firm initiated
Recalling firm
Noven Pharmaceuticals, Inc.

Original FDA data

Every field from FDA enforcement report D-1374-2012, exactly as published.

Show all FDA fields
City
Miami
State
FL
Status
Terminated
Country
United States
Event ID
61891
Address
11960 Sw 144th St
Code information
Lot #: 43783, Exp 01/12
Postal code
33186-6109
Report date
Jun 20, 2012
Product type
Drugs
Recall number
D-1374-2012
Classification
Class II
Recalling firm
Noven Pharmaceuticals, Inc.
Product quantity
244,320 patches
Termination date
May 23, 2013
Reason for recall
Miscalibrated and/or Defective Delivery System: Out of Specification results for mechanical peel force and/or the z-statistic value which relates to the patient's ability to remove the release liner from the patch adhesive prior to administration.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Daytrana (methylphenidate) transdermal system patch, Delivers 15 mg over 9 hours (1.6 mg/hr), 1 patch per pouch (NDC 54092-553-01), packaged in 30-count patches per box (NDC 54092-553-30), Rx only, Manufactured for Shire US Inc., Wayne, PA 19087; by Noven Pharmaceuticals, Inc., Miami, FL 33186.
Distribution pattern
Nationwide and Puerto Rico.
Recall initiation date
Jul 5, 2011
Initial firm notification
Letter
Center classification date
Jun 14, 2012

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1374-2012, published Jun 20, 2012. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls